Company Profile
A pioneer in the early detection, diagnosis, and early intervention of major chronic diseases
BioChain (Beijing) Science & Technology, Inc. was founded in 2006. As an industrial pioneer in early detection, diagnosis, and early intervention (hereinafter referred to as the "Three Early"), the company is committed to preventing cancer, cardiovascular and cerebrovascular diseases, infectious respiratory diseases, and other major chronic diseases. BioChain's mission is to serve the public with products and services with higher cost-effectiveness, better medication adherence, and broader applicability.
Historical Timeline and Key Milestones
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2008
2006
2023
Co-established the “Demonstration Zone and Base for Gastrointestinal Cancer Screening” with the China National Clinical Research Center for Digestive Diseases. BioChain’s various early diagnostic products have been integrated into the innovative screening program, which has led to nationwide promotion and demonstration.
The colorectal cancer early diagnostic kit, “思博定®,” and gastric cancer early diagnostic kit, “思博衛(wèi)®,” have both been officially recommended by CACA Technical Guidelines for Holistic Integrative Management of Cancer - Liquid Biopsy for the early detection and prognosis assessment of digestive tract cancers.
The gastric cancer early diagnostic kit, “思博衛(wèi)®,” has been recommended for the early screening, diagnosis, and follow-up monitoring of gastric cancer by China’s first expert consensus in the field of clinical medicine, “Chinese Expert Consensus on Detection Technologies for Early-Stage Gastric Cancer Screening.”
Established a strategic partnership with China Reform Health Management and Services Group Co., Ltd. (CRHMS) to jointly develop a new model for “the Prevention and Treatment of Chronic Diseases through Early Detection, Diagnosis, and Intervention,” aiming at promoting the development of an innovative health security model for chronic diseases.
The colorectal cancer early diagnostic kit, “思博定®,” and gastric cancer early diagnostic kit, “思博衛(wèi)®,” have both been included in the medical insurance system of Shanxi Province and Shaanxi Province.
As of July 2023，BioChain has reached over 160 utility patents approved both domestically and internationally.
2022
The early diagnostic kits for colorectal cancer, “思博定®,” gastric cancer, “思博衛(wèi)®,” esophageal cancer, “思博士®,” and liver cancer, “思博甘®,” were all chosen for the China National Key R&D Program during the 14th Five-year Plan Period.
The Joint Laboratory of Epigenetics Research, co-sponsored by Beijing Tiantan Hospital of Capital Medical University, and the National Clinical Research Center for Neurological Diseases, was formally established.
The Joint Laboratory of Epigenetics Research, initiated in collaboration with Beijing Tiantan Hospital of Capital Medical University and the China National Clinical Research Center for Neurological Diseases (NCRC-ND), was officially established.
The early diagnostic kit for colorectal cancer, “思博定®,” was included in the medical insurance system in Shanghai.
Awarded the “Beijing Intellectual Property Demonstration Unit” by the Beijing Municipal Intellectual Property Office.
Approved by the ISO13485 Quality Management System.
2021
Completed the Series B funding and received investment from the strategic partner, “China Reform Holdings Corporation Ltd.”
The early diagnostic kits for colorectal cancer, “思博定®,” and gastric cancer, “思博衛(wèi)®,” were both integrated into the medical insurance system in Beijing. Notably, “思博衛(wèi)®” is the only DNA methylation early diagnostic kit for gastric cancer that is covered by medical insurance nationwide.
Instrument for Automated Nucleic Acid Extraction and Purification (BN-4800) (智博利®) was approved by the Beijing Municipal Medical Products Administration for marketing authorization.
Participated in the World’s Largest cohort study of cerebrovascular accidents (or stroke) in epigenetic studies involving more than 10,000 participants, partnering with Beijing Tiantan Hospital of Capital Medical University.
Enrolled in the list of specialized and sophisticated SMEs in Beijing.
Approved for establishing the postdoctoral research workstation (Postdoctoral Program).
2020
Launched Series A funding and received investment from the industrial strategic partner “BOE Technology Group Co., Ltd.”
The early diagnostic kit for gastric cancer, “思博衛(wèi)®,” was approved by the NMPA as an innovative Class III medical device. It is the first (and only) approved DNA methylation diagnostic kit for gastric cancer in the world.
The early diagnostic kit for colorectal cancer, “思博定®,” was included in the medical insurance of Fujian Province, becoming the first early diagnostic product for colorectal cancer to be covered by medical insurance nationwide.
2019
The leading project, “The Transformation & Industrialization Project for Screening and Early Warning of Gastric Cancer,” received funding from the High-Precision Industry Cultivation Projects in Zhongguancun National Independent Innovation Demonstration Zone.
The leading project, “The Methylation-Based Automated Nucleic Acid Processing System in Early Diagnosis of Esophageal Cancer,” received funding from the Innovation Project of the Beijing Municipal Science & Technology Commission.
2018
Participated in the “Multi-Center Screening Project for Lung and Colorectal Cancer,” funded by the National Cancer Center of China and the National Cancer Institute in the U.S.
2017
The early diagnostic kit for lung cancer, “思博斐®,” was chosen for the National Key R&D Program during the 13th Five-year Plan Period of the Ministry of Science and Technology of the People's Republic of China.
2016
The early diagnostic kits for colorectal cancer, “思博定®,” gastric cancer, “思博衛(wèi)®,” and esophageal cancer, “思博士®,” were all chosen for the China National Key R&D Program during the 13th Five-Year Plan Period.
2015
The early diagnostic product for colorectal cancer, “思博定®,” was approved by the National Medical Products Administration (NMPA) as an innovative Class III medical device. It is the first blood-based DNA methylation diagnostic kit for colorectal cancer in China and has been recognized as one of the top ten most innovative in vitro diagnostic products of the year by the NMPA.
2014
The blood-based DNA methylation assay technique for colorectal cancer was exclusively introduced in China.
2008
Qualified as a National High-Tech Enterprise
2006
Founding of BioChain
Awards & Honors
-
The gastric cancer early detection kit, “思博衛(wèi)®,” was awarded the “Top Ten Innovative Technologies/Products for Tumor Biomarkers” at the Chinese Academic Conference on Tumor Biomarkers (CCTB 2022).
The esophageal cancer early detection kit, “思博士®,” won the “VB-Find Award” for being recognized as one of the TOP 100 most innovative medical technology products (solutions) in 2023.
-
The esophageal cancer early detection kit, “思博士®,” won the first prize in the “Selection of Innovative Technologies for Tumor Biomarkers and Integrative Medicine in Diagnosis and Treatment.”
The gastric cancer early detection kit, “思博衛(wèi)®,” won the “VB-Find Award” for being recognized as one of the TOP 100 most innovative medical technology products (solutions) in 2022.
The utility patent “A Combination of Healthy Epigenomics Markers and Its Application” won the “Science and Technology Innovation Outstanding Invention Achievement Award” from the China Scientists Forum.
It won the Genetic Testing Industry Annual Enterprise Award, the Genetic Testing Industry Technology Innovation Award, and the Genetic Testing Industry Annual Personality Award at the Second Gene Sequencing Industry Development Summit (GSIDS).
It won the 2022 “Gold Screen Awards” for the Leading Figure Award, the Leading Enterprise Award, the Breakthrough Innovation Award, and the Social Responsibility Award.
-
Won the “Tribute Innovation Award” of the Healthy China Action Demonstration V Innovation SHOW
-
The leading project, “The Application of Methylation-Based Automated Nucleic Acid Processing System in Early Detection and Screening of Esophageal Cancer Warning,” won the second prize in the In Vitro Diagnostics (IVD) Growth Group at the Third China Medical Devices Design & Entrepreneurship Competition (CMDDEC 2020)
-
The gastric cancer early detection kit, “思博衛(wèi)®,” won the second prize at the Second China Medical Devices Design & Entrepreneurship Competition (CMDDEC 2019)
-
Won the “Technological Innovation Contribution Award” in 2018 from the China Association of Technology Entrepreneurs (CATE)
-
The innovative research and clinical application project on tuberculosis diagnosis and treatment was awarded second place in the “China Medical Science and Technology Award.”
-
The Diagnostic Kit for Tuberculosis IgG Antibody (Colloidal Gold Immunochromatography) was awarded “The National New Products Program” certificate by the Ministry of Science and Technology of the People's Republic of China.
Partner Organizations
